Suppr超能文献

[不稳定型心绞痛的治疗。普萘洛尔、地尔硫䓬和莫西赛利的随机双盲研究]

[Treatment of unstable angina. A randomized double-blind study of propranolol, diltiazem and molsidomine].

作者信息

Nicolas G, Witchitz S, Beaufils P, Bory M, Bourdarias J P, Gilgenkrantz J M, Guize L, Kolsky H, Letac B, Sellier P

出版信息

Ann Cardiol Angeiol (Paris). 1986 Oct 30;35(8):501-4.

PMID:3545034
Abstract

A randomized, multicentric, double blind study attempted to compare in 41 patients hospitalized for unstable angina, the efficacy of diltiazem (D) 240 mg/day, propranolol (P) 160 mg/day and molsidomine (M) 8 mg/day. The patients included in the study presented one or several spontaneous angina episodes accompanied by a transient and significant lowering of ST and/or an inverted T wave without necrosis. The evaluation criteria were the occurrence of new angina pain and electrical alterations on a continuous Holter for 5 days. 11 patients received diltiazem, 13 patients received propranolol and 15 patients received molsidomine (including an early death). Clinically, the number of painful episodes per day and per patient goes, in an average, from 1.2 to 0.23 diltiazem, from 2.2 to 0.44 for propranolol and from 2.2 to 0.45 for molsidomine. Pain disappeared on the 5th day in 54.5 per cent of patients under diltiazem, 58.8 per cent of patients under propranolol and 53.5 per cent of patients under molsidomine. Electrically, the number of ischemic accidents per day and per patient was 0.45 under diltiazem, 2.12 under propranolol (0.53 in excluding one patient with latent angina) and 0.81 under molsidomine. The number of patients without any ischemic accident was 63.6 per cent under diltiazem, 53.8 per cent under propranolol and 40 per cent under molsidomine. In conclusion, diltiazem, propranolol, and molsidomine have a comparable efficacy in unstable angina. The association of these medications could have a synergistic effect.

摘要

一项随机、多中心、双盲研究试图对41例因不稳定型心绞痛住院的患者比较地尔硫䓬(D)240毫克/天、普萘洛尔(P)160毫克/天和莫西赛利(M)8毫克/天的疗效。纳入该研究的患者出现一次或几次自发性心绞痛发作,伴有ST段短暂且显著压低和/或T波倒置但无坏死。评估标准为持续5天的动态心电图上新发心绞痛疼痛和电改变的发生情况。11例患者接受地尔硫䓬,13例患者接受普萘洛尔,15例患者接受莫西赛利(包括1例早期死亡)。临床上,地尔硫䓬组每天每位患者的疼痛发作次数平均从1.2次降至0.23次,普萘洛尔组从2.2次降至0.44次,莫西赛利组从2.2次降至0.45次。地尔硫䓬组54.5%的患者在第5天时疼痛消失,普萘洛尔组为58.8%,莫西赛利组为53.5%。在电生理方面,地尔硫䓬组每天每位患者的缺血事件数为0.45次,普萘洛尔组为2.12次(排除1例隐匿性心绞痛患者后为0.53次),莫西赛利组为0.81次。地尔硫䓬组无任何缺血事件的患者比例为63.6%,普萘洛尔组为53.8%,莫西赛利组为40%。总之,地尔硫䓬、普萘洛尔和莫西赛利在不稳定型心绞痛中具有相当的疗效。这些药物联合使用可能具有协同作用。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验